- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01807598
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
Study Overview
Status
Intervention / Treatment
Detailed Description
Brentuximab vedotin is an antibody with a covalently attached toxin. The antibody portion targets the protein CD30 on the surface of cells, and the toxin acts against those cells.
PRIMARY OBJECTIVES:
I. To evaluate the response rate to SGN-35 (brentuximab vedotin) in patients with tumor necrosis factor receptor superfamily, member 8 (CD30+) advanced systemic mastocytosis (SM) (ASM or mast cell leukemia [MCL] with or without an associated hematological clonal non-mast cell lineage disease [AHNMD]).
SECONDARY OBJECTIVES:
I. To evaluate the tolerability and safety profile of SGN-35 in patients with SM.
II. To evaluate expression of CD30 on neoplastic mast cells before and during therapy with SGN-35.
III. To evaluate changes in mastocytosis related symptom scores and quality of life (QOL) using a modified Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF).
IV. To evaluate the duration of response (DoR) and time to response (TTR). V. To evaluate progression-free survival (PFS).
OUTLINE:
Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 weeks for 1 year and then every 12 weeks thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University, School of Medicine
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
- Life expectancy > 12 weeks
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN), if caused by ASM/MCL =< 5 x ULN
- Serum direct bilirubin =< 1.5 x ULN; if considered related to ASM/MCL =< 3 x ULN
- Serum creatinine =< 2.0 mg/dL
- A diagnosis of systemic mastocytosis (SM) per 2008 World Health Organization (WHO) Criteria
- Neoplastic mast cells must express CD30 by immunohistochemistry or flow cytometry
- At least one of the eligible organ damage findings as defined by the international consensus response criteria
- Females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug
- Females of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test result within 7 days prior to the first dose of SGN-35
- Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy
Exclusion Criteria:
- Unwilling or unable to comply with the protocol
- Any other concurrent severe known disease (except carcinoma in-situ) or concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, or active uncontrolled infection) which could compromise participation in the study
- History of another primary malignancy that has not been in remission for at least 3 years (the following are exempt from the 3-year limit: non-melanoma skin cancer, fully excised melanoma in situ [stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolaou [PAP] smear)
- Cardiovascular disease including congestive heart failure grade III or IV according to the New York Heart Association (NYHA) classification, left ventricular ejection fraction of < 50%, myocardial infarction within previous 6 months or poorly controlled hypertension
- Pregnant or lactating
- Neuropathy greater than or equal to grade 2
- Known hypersensitivity to any excipient contained in the drug formulation
- Confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
- Presenting with an AHNMD requiring immediate cytoreductive therapy or targeted drugs (eg, AML)
- Received any investigational agent, chemotherapy, interferon-alfa, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to Day 1
- Received hematopoietic growth factor support within 14 days of Day 1 of SGN-35
- Use of prednisone (or equivalent corticosteroid dose) for SM up to 10 mg/day or its equivalent is allowed, but it cannot have been started during screening; patients who are on prednisone up to 10 mg/day for medical problems unrelated to SM are also permitted on study
- Presence of FIP1L1-PDGFR-alpha fusion even with resistance to imatinib
- Received any treatment with SGN-35 prior to study entry
- Any surgical procedure within 14 days of Day 1, excluding central venous catheter placement or other minor procedures (eg, skin biopsy)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brentuximab vedotin
Subjects receive a 30-minute IV infusion of brentuximab vedotin once every 21 days for 8 courses, in the absence of disease progression or unacceptable toxicity.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement)
Time Frame: Up to 1 year
|
Overall response rate (ORR) is sum of complete response (CR); partial response (PR); and clinical improvement (CI) in 1 year, ie, ORR=CR+PR+CI. The outcome is the number of participants without dispersion. CR is following with response duration(RD) ≥12 weeks (wk)
Any of:
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brentuximab Vedotin Toxicity
Time Frame: Up to 1 year
|
Toxicity was assessed as the number of adverse events considered possibly, probably, or definitely-related to treatment with brentuximab vedotin.
The outcome is reported as the total number of related events, a number without dispersion, and the number of related events (without dispersion) considered to be either a hematologic toxicity or non-hematologic toxicity.
|
Up to 1 year
|
Percent Change of CD30 Expression on Neoplastic Mast Cells
Time Frame: Baseline and up to 1 year
|
The presence of the CD30 marker (epitope) on neoplastic (cancerous) mast cells in core bone marrow biopsy samples was assessed by immunohistochemical methods, before and after brentuximab vedotin treatment.
CD30 is a member of the TNF-receptor (TNF-R) superfamily, and is a transmembrane glycoprotein receptor that is normally at very low levels on the surface of activated T-cells.
Overexpression of the CD30 marker is indicative of T-cell lymphoproliferative disorders and neoplastic mast cells, and the effect of a particular treatment on CD30 expression may be related to the efficacy of that treatment.
The outcome is reported as the median percentage change in the level of CD30 detected, reported with full range.
|
Baseline and up to 1 year
|
Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Total Symptom Score
Time Frame: Up to 1 year
|
The clinical effect of patient symptoms associated with systemic mastocytosis or mast cell leukemia were assessed with the patient-reported outcome survey entitled Myeloproliferative Neoplasm Symptom Assessment Form with Mast Cell Disorder Symptoms [(MPN-SAF(MCD)].
The MPN-SAF(MCD) is a 36-question survey, with possible responses ranged from 0 to 10, with 0 indicating not present or no effect; 1 meaning present but most favorable; and 10 meaning worst imaginable (least favorable).
Total range is 0 to 360, with 0 being best possible, and 360 being worst possible.
Total symptom score is calculated as the sum of the individual survey scores reported at baseline and after treatment, with lower numbers indicating less effect, and larger numbers indicated greater effect.
The outcome is reported as mean score value with dispersion.
|
Up to 1 year
|
Quality of Life (QoL) Score Using a Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)
Time Frame: Up to 1 year
|
Overall quality of life (QoL) was assessed by a single specific question from the 36-question Myeloproliferative Neoplasm Symptom Assessment Form with Mast Cell Disorder Symptoms [(MPN-SAF(MCD)] survey.
Possible responses for theQoL question range from 0 to 10, with 0 indicating "as good as it can be" (most favorable), and 10 meaning "as bad as it can be" (least favorable).
The QoL score was obtained at baseline and after treatment.
The outcome is reported as mean score with dispersion.
|
Up to 1 year
|
Duration of Response (DOR)
Time Frame: Up to 1 year
|
Duration of response (DOR) is defined as the time from the start of the first confirmed response until the date of the first documented and confirmed disease progression or death due to ASM or MCL.
For participants with a confirmed clinical response, the outcome was to be reported as the median DOR with standard deviation.
|
Up to 1 year
|
Time to Response (TTR)
Time Frame: Up to 1 year
|
Time to response (TTR) is defined as the time from the date of start of treatment to the date of first confirmed response.
For participants with a confirmed clinical response, the outcome was to be reported as the median TTR with standard deviation.
|
Up to 1 year
|
Progression-free Survival (PFS)
Time Frame: Up to 1 year
|
Progression-free survival (PFS) is defined as the time from the date of start of treatment until disease progression; death; or initiation of new therapy. The outcome is reported as the mean number of days of PFS, with 95% confidence interval. Progressive disease (PD) is any of the following:
|
Up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jason Gotlib, Stanford University Hospitals and Clinics
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Hypersensitivity
- Neoplasms, Connective Tissue
- Immune Complex Diseases
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia
- Mastocytosis
- Mastocytosis, Systemic
- Leukemia, Mast-Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Brentuximab Vedotin
- Immunoconjugates
Other Study ID Numbers
- IRB-25727 (Other Identifier: Stanford IRB)
- NCI-2013-00537 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 107011 (Other Identifier: Organon)
- HEMMPD0016 (Other Identifier: OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Mastocytosis
-
University Hospital, ToulouseNot yet recruiting
-
Blueprint Medicines CorporationActive, not recruitingIndolent Systemic MastocytosisCanada, United States, Spain, United Kingdom, Germany, Belgium, Switzerland, Italy, Netherlands, Denmark, France, Norway, Sweden
-
University Hospital, ToulouseRecruitingMastocytosis, Indolent SystemicFrance
-
AB ScienceRecruitingIndolent Systemic MastocytosisFrance, Netherlands, Germany, United Kingdom, Russian Federation, Poland, Romania, Ukraine
-
Allakos Inc.CompletedIndolent Systemic MastocytosisGermany
-
University Hospital, ToulouseCompletedIndolent Systemic Mastocytosis | Cutaneous MastocytosisFrance
-
Blueprint Medicines CorporationAnalysis Group, Inc.CompletedMast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematological NeoplasmUnited States, Austria, Germany, Spain, United Kingdom
-
Patara PharmaCompletedSystemic Mastocytosis | Mastocytosis | Indolent Systemic MastocytosisFrance, Germany, Spain, Italy, Netherlands
-
University Medical Center GroningenUnknown
-
Blueprint Medicines CorporationCompletedMast Cell Leukemia | Aggressive Systemic Mastocytosis | Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease | Relapsed or Refractory Myeloid MalignanciesUnited States, United Kingdom
Clinical Trials on Brentuximab vedotin
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, France
-
Seagen Inc.TerminatedSystemic Lupus ErythematosusUnited States
-
University Hospital, CaenRecruiting
-
Washington University School of MedicineSeagen Inc.CompletedMyelodysplastic Syndromes | Leukemia, Acute Myeloid | Leukemia, Lymphoblastic,AcuteUnited States
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, Germany
-
Fondazione Italiana Linfomi ONLUSCompletedRelapsed/Refractory Hodgkin's LymphomaItaly
-
Seagen Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States
-
Seagen Inc.Millennium Pharmaceuticals, Inc.No longer availableLymphoma, Non-Hodgkin | Lymphoma, T-Cell, Cutaneous | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, United Kingdom, Belgium, Serbia, Australia, Bulgaria, France, Germany, Hungary, Italy, Poland, Romania, Russian Federation, Spain, Switzerland
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterCompletedRelapsed or Refractory EBV-and CD30-positive LymphomasKorea, Republic of
-
Samsung Medical CenterMillennium Pharmaceuticals, Inc.CompletedNon-Hodgkin LymphomaKorea, Republic of